The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) is a huge mover today! The stock increased 3.58% or $0.19 during the last trading session, hitting $5.5. About 1.41 million shares traded hands. Keryx Biopharmaceuticals (NASDAQ:KERX) has risen 32.09% since February 29, 2016 and is uptrending. It has outperformed by 19.87% the S&P500.
The move comes after 5 months positive chart setup for the $600.52M company. It was reported on Oct, 4 by Barchart.com. We have $9.02 PT which if reached, will make NASDAQ:KERX worth $384.33 million more.
Analysts await Keryx Biopharmaceuticals (NASDAQ:KERX) to report earnings on November, 3. They expect $-0.22 earnings per share, up 24.14% or $0.07 from last year’s $-0.29 per share. After $-0.42 actual earnings per share reported by Keryx Biopharmaceuticals for the previous quarter, Wall Street now forecasts -47.62% EPS growth.
Keryx Biopharmaceuticals (NASDAQ:KERX) Ratings Coverage
Out of 14 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 rate it a “Buy”, 2 “Sell”, while 6 “Hold”. This means 43% are positive. Keryx Biopharmaceuticals has been the topic of 28 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Buy” rating by Maxim Group on Tuesday, March 29. The firm has “Sell” rating by BTIG Research given on Thursday, August 6. The rating was upgraded by Morgan Stanley to “Equal-Weight” on Monday, October 5. TH Capital maintained Keryx Biopharmaceuticals (NASDAQ:KERX) on Thursday, July 23 with “Buy” rating. The rating was initiated by Morgan Stanley on Thursday, August 13 with “Underweight”. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Buy” rating by TH Capital on Monday, August 10. Maxim Group maintained the stock with “Buy” rating in Thursday, August 6 report. The firm has “Outperform” rating given on Friday, February 26 by Raymond James. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Buy” rating by Stifel Nicolaus on Friday, February 26. As per Tuesday, August 2, the company rating was downgraded by FBR Capital.
According to Zacks Investment Research, “Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.”
Insitutional Activity: The institutional sentiment decreased to 0.49 in Q2 2016. Its down 1.00, from 1.49 in 2016Q1. The ratio is negative, as 29 funds sold all Keryx Biopharmaceuticals shares owned while 43 reduced positions. 12 funds bought stakes while 23 increased positions. They now own 64.01 million shares or 1.49% less from 64.98 million shares in 2016Q1.
Century Capital Mgmt Limited Liability Corp holds 272,773 shares or 0.2% of its portfolio. Lmr Llp has 18,824 shares for 0.02% of their US portfolio. Parametric Portfolio Limited Liability Com has invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). Credit Suisse Ag holds 0% or 129,319 shares in its portfolio. Blackrock Institutional Trust Na owns 2.41M shares or 0% of their US portfolio. Northern Trust, a Illinois-based fund reported 954,397 shares. Manufacturers Life Insurance The has invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). State Board Of Administration Of Florida Retirement System owns 64,782 shares or 0% of their US portfolio. Group Incorporated One Trading L P holds 0.01% or 91,444 shares in its portfolio. Moreover, Ladenburg Thalmann has 0% invested in Keryx Biopharmaceuticals (NASDAQ:KERX) for 5,575 shares. Stifel accumulated 0% or 25,501 shares. Nationwide Fund accumulated 0% or 52,010 shares. Sei Invs Co has 491 shares for 0% of their US portfolio. Fmr Lc accumulated 0% or 3.17 million shares. Oppenheimer & accumulated 0.01% or 62,316 shares.
Insider Transactions: Since April 5, 2016, the stock had 0 insider purchases, and 8 selling transactions for $104,533 net activity. 1,060 shares were sold by Adams Brian, worth $5,353 on Friday, April 15. Another trade for 4,766 shares valued at $24,831 was made by Neylan John F. on Monday, April 25. 1,873 Keryx Biopharmaceuticals (NASDAQ:KERX) shares with value of $10,152 were sold by Madison Greg. Holmes Scott A sold $36,322 worth of stock.
More notable recent Keryx Biopharmaceuticals (NASDAQ:KERX) news were published by: Seekingalpha.com which released: “Keryx Biopharmaceuticals Is Likely To Fully Recover From August” on October 03, 2016, also Fool.com with their article: “Here’s Why Keryx Biopharmaceuticals Plunged 44.3% in August” published on September 06, 2016, Finance.Yahoo.com published: “October 3rd Deadline in Lawsuit for Investors in shares of Keryx …” on September 28, 2016. More interesting news about Keryx Biopharmaceuticals (NASDAQ:KERX) were released by: Prnewswire.com and their article: “INVESTOR ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors …” published on September 08, 2016 as well as Prnewswire.com‘s news article titled: “Robbins Geller Rudman & Dowd LLP Updates Investors Regarding Securities Class …” with publication date: September 07, 2016.
KERX Company Profile
Keryx Biopharmaceuticals, Inc., incorporated on October 22, 1998, is a biopharmaceutical company. The Firm is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Firm operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.